Salute e Benessere

H.I.G. Realty Announces Strategic Partnership with Queen Mary BioEnterprises…

Additionally, the development of a state-of-the-art incubator space and its shared services will create a venture-building environment and ecosystem, critical in attracting startup companies and spinouts. QMB's extensive experience operating incubator spaces will also help deliver long-term, high-quality jobs to the Whitechapel area, foster career pathways, and promote education in the life sciences and STEM sectors. Additionally, the development of a state-of-the-art incubator space and its...
PR Newswire
23/12/2024

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling…

Under the terms of the Marketing Agreement, OBI grants GlyTech rights to market and promote OBI's GlycOBI® ADC enabling technologies, powered by EndoSymeOBI®, to potential pharma and biotech partners in Japan. GlyTech will also be a key supplier of glycans in Japan. Under the terms of the Material Transfer Agreement, OBI will transfer some of its cutting-edge materials to GlyTech for research in advancing the efficient production of glycans for ADCs.Heidi Wang, Ph.D., OBI Pharma's Chief...
Nasdaq GlobeNewswire
23/12/2024

THE STATE OF GLOBAL OPTIMISM REVEALED BY LG IN NEW SURVEY

The survey, conducted across 16 markets, provides extensive data on global optimism, its drivers and the demographics that feel the most optimistic and happy. The global average optimism score is 7.49/10. France, the UK and Australia were revealed to be among the least optimistic countries, scoring 14.5 percent below the average. Conversely, Saudi Arabia (12 percent above), India (10.8 percent above) and the UAE (8.1 percent above) were the most optimistic. Consumers were most optimistic about…
PR Newswire
23/12/2024

Implantica to be included in Nasdaq's First North 25 index

Implantica founder and CEO, Peter Forsell, says, "It is an honor to be selected for inclusion in the FN 25 index and validates the high interest Implantica has received from investors, especially since we have submitted the first two of three modules of RefluxStop's PMA application to FDA, for approval to sell in the U.S. Implantica founder and CEO,Peter Forsell, says, "It is an honor to be selected for inclusion in the FN 25 index and validates the high interest Implantica has…
PR Newswire
23/12/2024

Basilea is awarded additional CARB-X funding to develop new drug candidate from…

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it...
Nasdaq GlobeNewswire
23/12/2024

Press Release: Sanofi initiates phase 3 program for PCV21 and expands…

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccinesPneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers Paris, December 23, 2024. Sanofi and SK bioscience have...
Nasdaq GlobeNewswire
23/12/2024

Press release: Sequana Medical Announces US FDA Approval of alfapump® for the…

Sequana Medical Announces US FDA Approval of alfapump ®for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis alfapump ®is the first US approved active implantable medical device (Class III) for the treatment of recurrent or refractory ascites due to liver cirrhosisPMA Approval and FDA Breakthrough Device DesignationUS market opportunity estimated at over $2 billion in 2025, growing at 9% 1due to MASH/NASH 2and alcoholic liver diseaseUS...
Nasdaq GlobeNewswire
23/12/2024

Aptamer developed by HKBU for treating rare bone disease 'X-linked…

Professor Zhang Ge, Associate Dean (Research) of Chinese Medicine and Director of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at HKBU, and Professor Zhang Zhenlin, Director of Osteoporosis and Bone Diseases of the Shanghai Sixth People's Hospital, along with Aptacure Therapeutics Ltd., have developed a long-acting sclerostin-loop3 oligonucleotide aptamer for the treatment of XLH. This aptamer has been granted Orphan Drug Designation and Pediatric…
PR Newswire
23/12/2024

ZINZINO AB (PUBL.): ENTERS INTO AGREEMENT TO PROVIDE DIP FINANCING TO ZURVITA…

Zurvita is a direct selling health company with operations in the United States, Canada and Mexico. The brand portfolio offers a range of innovative health and wellness products. The business has total annual sales of approximately USD 30 million with good gross margins. A potential transaction with Zinzino is expected to add growth through the synergies arising from the joint networks, combined with Zinzino's test-based product concept. The profitability of the Company will thus be able to…
PR Newswire
22/12/2024

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), December 20, 2024 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.BlackRock, Inc.On December 19, 2024, Nyxoah received a transparency notification from...
Nasdaq GlobeNewswire
20/12/2024

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024…

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.In order to participate, please register in advancehere to obtain a local or toll-free phone number and your...
Nasdaq GlobeNewswire
20/12/2024

Renovaro Regains Compliance with NASDAQ Listing Requirement

Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company's security will continue to be listed and traded on The Nasdaq Stock Market and this matter is now closed...
Nasdaq GlobeNewswire
20/12/2024

Press Release: Sequana Medical announces results of Extraordinary General…

Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible FinancingGhent, Belgium – 20 December 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the proposed resolution submitted to the extraordinary general shareholders' meeting was approved at the meeting held today at…
Nasdaq GlobeNewswire
20/12/2024

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031—a clear indicator of oncology's rapid growth and critical importance. The article continued: Additionally, theAmerican Cancer Societyhas spotlighted an alarming rise incancer...
PR Newswire
20/12/2024

Digital Access, AI, and 99% e-Prescriptions: Estonia's e-Health Revolution and…

The success of Estonia's e-health system is not only a source of national pride but serves as a valuable model for regions like the GCC, where rapid population growth and an increasing demand for quality healthcare require innovative solutions to manage healthcare resources efficiently and ensure patient satisfaction. The success ofEstonia'se-health system is not only a source of national pride but serves as a valuable model for regions like the GCC, where rapid population growth and an...
PR Newswire
20/12/2024

Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care

News Release Exclusive Industry Role : Avextra is the industry partner in a groundbreaking project focused on psychedelic-assisted therapy for patients in palliative care suffering from depression. Pioneering Research : This multi-centre Phase 2 clinical trial spans four European countries and is sponsored by the University Medical Center Groningen in the Netherlands. Collaborative Effort : 19 partner organizations (universities, companies, foundations, institutes, and patient...
Nasdaq GlobeNewswire
20/12/2024

Global Live Cell Imaging Market: Advances and Growth Prospects

This report covers the global market for live cell imaging, focusing on the tools, software, and services used to study living cells. It breaks down the market and offers insights into products, technologies, major users, and regional trends, Highlights include industry operations, innovations, growth opportunities, and profiles of top companies. This report covers the global market for live cell imaging, focusing on the tools, software, and services used to study living cells. It breaks down...
PR Newswire
20/12/2024

Result of AGM

DXS INTERNATIONAL PLC (AQSE: DXSP)Result of DXS AGM 2024 The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting ("AGM") held yesterday were duly passed.All resolutions were passed on a poll and the votes received from shareholders on each resolution put to the AGM...
Nasdaq GlobeNewswire
20/12/2024

Medical Aesthetics Market to Hit US$ 35.32 Billion by 2030 with 12.8% CAGR |…

Browse in-depth TOC on "Medical Aesthetics Market" Browse in-depth TOC on "Medical Aesthetics Market" 253 - Tables 50 - Figures 310 - Pages Based on the product,the medical aesthetics market is categorized into facial aesthetic products, cosmetics implants, skin aesthetic devices, body contouring devices, physician-dispensed cosmeceuticals and skin lighteners, hair removal devices, tattoo removal devices, thread lift products, Physician- dispensed eyelash products and nail...
PR Newswire
20/12/2024

Artificial Intelligence in Oncology Market to Hit US$ 11.52 Billion by 2030 with…

Browse in-depth TOC on "Artificial Intelligence in Oncology Market" Browse in-depth TOC on "Artificial Intelligence in Oncology Market" 250 - Tables 50 - Figures 300 - Pages By application, the drug discovery segment holds significant share in AI in oncology market. This large share is anticipated due to the rising burden of cancer coupled with technological advancements that enhance understanding of disease mechanisms. Further, this segment is classified into drug…
PR Newswire
20/12/2024

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm…

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec.20, 2024(GLOBE NEWSWIRE) --Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic collaboration with Nebul ( www.nebul.com ) a leading AI...
Nasdaq GlobeNewswire
20/12/2024

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

"We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth," said Dr. Chunlin Chen, Founder and CEO of Medicilon. "Her extensive expertise and global perspective align with our vision of driving innovation and advancing our international presence." "We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth," said Dr.Chunlin Chen, Founder and CEO of Medicilon. "Her extensive expertise and global perspective align…
PR Newswire
20/12/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 December 2024– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…
Nasdaq GlobeNewswire
20/12/2024

SciBase letter from the CEO

We have successfully broadened our presence in the US market with more clinics in new states using Nevisense. We have added individual clinics that diagnose and treat a large number of patients with skin cancer to our target groups, which overall expands SciBase business opportunity. In areas with no reimbursement, we now offer the option of paying directly, a so-called cash-pay model. We are currently testing and evaluating this model in California, the model is proven for other technologies…
PR Newswire
20/12/2024
Altri  Comunicati